TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

NCT ID: NCT01493505

Last Updated: 2017-02-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

1015 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fallopian Tube Cancer Ovarian Cancer Peritoneal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Placebo Paclitaxel Carboplatin

Group Type PLACEBO_COMPARATOR

Paclitaxel

Intervention Type DRUG

Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)

AMG 386 Placebo

Intervention Type DRUG

AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)

Carboplatin

Intervention Type DRUG

Carboplatin AUC 5 or 6 IV Q3W (6 cycles)

AMG 386

AMG 386 Paclitaxel Carboplatin

Group Type ACTIVE_COMPARATOR

AMG 386

Intervention Type DRUG

AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)

Paclitaxel

Intervention Type DRUG

Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)

Carboplatin

Intervention Type DRUG

Carboplatin AUC 5 or 6 IV Q3W (6 cycles)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AMG 386

AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)

Intervention Type DRUG

Paclitaxel

Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)

Intervention Type DRUG

AMG 386 Placebo

AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)

Intervention Type DRUG

Carboplatin

Carboplatin AUC 5 or 6 IV Q3W (6 cycles)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female subjects 18 years of age or older with FIGO Stages III-IV epithelial ovarian, primary peritoneal or fallopian tube cancer with an indication for first-line treatment with paclitaxel and carboplatin x 6 cycles (Subjects with pseudomyxoma, mesothelioma, adenocarcinoma with an unknown primary tumour, carcinosarcoma, sarcoma, mucinous or neuroendocrine histology are excluded
* Subjects with FIGO Stage IIIA or IIIB disease must have undergone PDS for ovarian, primary peritoneal or fallopian tube cancer within 12 weeks prior to randomization
* Subjects with FIGO Stage IIIC or IV disease must either:
* Undergo PDS for epithelial ovarian, primary peritoneal or fallopian tube cancer within 12 weeks prior to randomization or
* Plan to have IDS following 3 cycles of paclitaxel and carboplatin plus AMG 386 or AMG 386 placebo for biopsy proven epithelial ovarian, primary peritoneal or fallopian tube cancer
* ECOG performance status of 0 or 1
* Adequate bone marrow, renal and hepatic function

Exclusion Criteria

* Prior use of any anticancer therapy or experimental therapy for epithelial ovarian, primary peritoneal or fallopian tube cancer
* Previous abdominal and/or pelvic external beam radiotherapy
* History of central nervous metastasis
* History of arterial or venous thromboembolism within 12 months prior to randomization
* Clinically significant cardiovascular disease within 12 months prior to randomization
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Amgen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Namur, , Belgium

Site Status

Research Site

Ostend, , Belgium

Site Status

Research Site

Sint-Niklaas, , Belgium

Site Status

Research Site

Turnhout, , Belgium

Site Status

Research Site

Wilrijk, , Belgium

Site Status

Research Site

Yvoir, , Belgium

Site Status

Research Site

Calgary, Alberta, Canada

Site Status

Research Site

Edmonton, Alberta, Canada

Site Status

Research Site

Halifax, Nova Scotia, Canada

Site Status

Research Site

Kingston, Ontario, Canada

Site Status

Research Site

Birmingham, Alabama, United States

Site Status

Research Site

Mobile, Alabama, United States

Site Status

Research Site

Anchorage, Alaska, United States

Site Status

Research Site

Gilbert, Arizona, United States

Site Status

Research Site

Peoria, Arizona, United States

Site Status

Research Site

Phoenix, Arizona, United States

Site Status

Research Site

Phoenix, Arizona, United States

Site Status

Research Site

Tucson, Arizona, United States

Site Status

Research Site

Tucson, Arizona, United States

Site Status

Research Site

Berkeley, California, United States

Site Status

Research Site

Burbank, California, United States

Site Status

Research Site

Concord, California, United States

Site Status

Research Site

Corona, California, United States

Site Status

Research Site

La Jolla, California, United States

Site Status

Research Site

Long Beach, California, United States

Site Status

Research Site

Los Angeles, California, United States

Site Status

Research Site

Orange, California, United States

Site Status

Research Site

Oxnard, California, United States

Site Status

Research Site

Rancho Mirage, California, United States

Site Status

Research Site

Sacramento, California, United States

Site Status

Research Site

Sacramento, California, United States

Site Status

Research Site

San Diego, California, United States

Site Status

Research Site

Aurora, Colorado, United States

Site Status

Research Site

Englewood, Colorado, United States

Site Status

Research Site

Bridgeport, Connecticut, United States

Site Status

Research Site

Farmington, Connecticut, United States

Site Status

Research Site

Hartford, Connecticut, United States

Site Status

Research Site

New Britain, Connecticut, United States

Site Status

Research Site

Stamford, Connecticut, United States

Site Status

Research Site

Clearwater, Florida, United States

Site Status

Research Site

Hollywood, Florida, United States

Site Status

Research Site

Miami, Florida, United States

Site Status

Research Site

Orlando, Florida, United States

Site Status

Research Site

Orlando, Florida, United States

Site Status

Research Site

St. Petersburg, Florida, United States

Site Status

Research Site

Tampa, Florida, United States

Site Status

Research Site

Augusta, Georgia, United States

Site Status

Research Site

Gainesville, Georgia, United States

Site Status

Research Site

Macon, Georgia, United States

Site Status

Research Site

Savannah, Georgia, United States

Site Status

Research Site

Honolulu, Hawaii, United States

Site Status

Research Site

Chicago, Illinois, United States

Site Status

Research Site

Chicago, Illinois, United States

Site Status

Research Site

Chicago, Illinois, United States

Site Status

Research Site

Decatur, Illinois, United States

Site Status

Research Site

Evanston, Illinois, United States

Site Status

Research Site

Hinsdale, Illinois, United States

Site Status

Research Site

Joliet, Illinois, United States

Site Status

Research Site

Maywood, Illinois, United States

Site Status

Research Site

Oak Lawn, Illinois, United States

Site Status

Research Site

Park Ridge, Illinois, United States

Site Status

Research Site

Urbana, Illinois, United States

Site Status

Research Site

Indianapolis, Indiana, United States

Site Status

Research Site

Indianapolis, Indiana, United States

Site Status

Research Site

Indianapolis, Indiana, United States

Site Status

Research Site

Munster, Indiana, United States

Site Status

Research Site

South Bend, Indiana, United States

Site Status

Research Site

Ames, Iowa, United States

Site Status

Research Site

Iowa City, Iowa, United States

Site Status

Research Site

Kansas City, Kansas, United States

Site Status

Research Site

Edgewood, Kentucky, United States

Site Status

Research Site

Lexington, Kentucky, United States

Site Status

Research Site

Covington, Louisiana, United States

Site Status

Research Site

Lafayette, Louisiana, United States

Site Status

Research Site

Scarborough, Maine, United States

Site Status

Research Site

Baltimore, Maryland, United States

Site Status

Research Site

Baltimore, Maryland, United States

Site Status

Research Site

Baltimore, Maryland, United States

Site Status

Research Site

Boston, Massachusetts, United States

Site Status

Research Site

Burlington, Massachusetts, United States

Site Status

Research Site

Danvers, Massachusetts, United States

Site Status

Research Site

Worcester, Massachusetts, United States

Site Status

Research Site

Detroit, Michigan, United States

Site Status

Research Site

Detroit, Michigan, United States

Site Status

Research Site

Kalamazoo, Michigan, United States

Site Status

Research Site

Minneapolis, Minnesota, United States

Site Status

Research Site

Rochester, Minnesota, United States

Site Status

Research Site

Saint Louis Park, Minnesota, United States

Site Status

Research Site

Jackson, Mississippi, United States

Site Status

Research Site

Kansas City, Missouri, United States

Site Status

Research Site

St Louis, Missouri, United States

Site Status

Research Site

Billings, Montana, United States

Site Status

Research Site

Lincoln, Nebraska, United States

Site Status

Research Site

Las Vegas, Nevada, United States

Site Status

Research Site

Reno, Nevada, United States

Site Status

Research Site

Lebanon, New Hampshire, United States

Site Status

Research Site

Hackensack, New Jersey, United States

Site Status

Research Site

Neptune City, New Jersey, United States

Site Status

Research Site

Voorhees Township, New Jersey, United States

Site Status

Research Site

Albuquerque, New Mexico, United States

Site Status

Research Site

Albuquerque, New Mexico, United States

Site Status

Research Site

Albany, New York, United States

Site Status

Research Site

Brightwaters, New York, United States

Site Status

Research Site

Buffalo, New York, United States

Site Status

Research Site

Jamaica, New York, United States

Site Status

Research Site

Lake Success, New York, United States

Site Status

Research Site

New York, New York, United States

Site Status

Research Site

New York, New York, United States

Site Status

Research Site

New York, New York, United States

Site Status

Research Site

Syracuse, New York, United States

Site Status

Research Site

The Bronx, New York, United States

Site Status

Research Site

Asheville, North Carolina, United States

Site Status

Research Site

Burlington, North Carolina, United States

Site Status

Research Site

Chapel Hill, North Carolina, United States

Site Status

Research Site

Charlotte, North Carolina, United States

Site Status

Research Site

Concord, North Carolina, United States

Site Status

Research Site

Durham, North Carolina, United States

Site Status

Research Site

Wilmington, North Carolina, United States

Site Status

Research Site

Winston-Salem, North Carolina, United States

Site Status

Research Site

Winston-Salem, North Carolina, United States

Site Status

Research Site

Fargo, North Dakota, United States

Site Status

Research Site

Akron, Ohio, United States

Site Status

Research Site

Canton, Ohio, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Cleveland, Ohio, United States

Site Status

Research Site

Cleveland, Ohio, United States

Site Status

Research Site

Cleveland, Ohio, United States

Site Status

Research Site

Columbus, Ohio, United States

Site Status

Research Site

Columbus, Ohio, United States

Site Status

Research Site

Kettering, Ohio, United States

Site Status

Research Site

Mayfield Heights, Ohio, United States

Site Status

Research Site

Toledo, Ohio, United States

Site Status

Research Site

Oklahoma City, Oklahoma, United States

Site Status

Research Site

Tulsa, Oklahoma, United States

Site Status

Research Site

Bend, Oregon, United States

Site Status

Research Site

Abington, Pennsylvania, United States

Site Status

Research Site

Bethlehem, Pennsylvania, United States

Site Status

Research Site

Philadelphia, Pennsylvania, United States

Site Status

Research Site

Philadelphia, Pennsylvania, United States

Site Status

Research Site

Pittsburgh, Pennsylvania, United States

Site Status

Research Site

Pittsburgh, Pennsylvania, United States

Site Status

Research Site

Radnor, Pennsylvania, United States

Site Status

Research Site

West Reading, Pennsylvania, United States

Site Status

Research Site

Providence, Rhode Island, United States

Site Status

Research Site

Charleston, South Carolina, United States

Site Status

Research Site

Columbia, South Carolina, United States

Site Status

Research Site

Greenville, South Carolina, United States

Site Status

Research Site

Greenville, South Carolina, United States

Site Status

Research Site

Sioux Falls, South Dakota, United States

Site Status

Research Site

Chattanooga, Tennessee, United States

Site Status

Research Site

Austin, Texas, United States

Site Status

Research Site

Austin, Texas, United States

Site Status

Research Site

Bedford, Texas, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

Galveston, Texas, United States

Site Status

Research Site

Houston, Texas, United States

Site Status

Research Site

San Antonio, Texas, United States

Site Status

Research Site

The Woodlands, Texas, United States

Site Status

Research Site

Ogden, Utah, United States

Site Status

Research Site

Burlington, Vermont, United States

Site Status

Research Site

Annandale, Virginia, United States

Site Status

Research Site

Charlottesville, Virginia, United States

Site Status

Research Site

Norfolk, Virginia, United States

Site Status

Research Site

Roanoke, Virginia, United States

Site Status

Research Site

Winchester, Virginia, United States

Site Status

Research Site

Woodbridge, Virginia, United States

Site Status

Research Site

Seattle, Washington, United States

Site Status

Research Site

Tacoma, Washington, United States

Site Status

Research Site

Wenatchee, Washington, United States

Site Status

Research Site

Green Bay, Wisconsin, United States

Site Status

Research Site

Green Bay, Wisconsin, United States

Site Status

Research Site

Marshfield, Wisconsin, United States

Site Status

Research Site

Milwaukee, Wisconsin, United States

Site Status

Research Site

Milwaukee, Wisconsin, United States

Site Status

Research Site

Milwaukee, Wisconsin, United States

Site Status

Research Site

Oshkosh, Wisconsin, United States

Site Status

Research Site

Sheboygan, Wisconsin, United States

Site Status

Research Site

Waukesha, Wisconsin, United States

Site Status

Research Site

Wausau, Wisconsin, United States

Site Status

Research Site

West Allis, Wisconsin, United States

Site Status

Research Site

Graz, , Austria

Site Status

Research Site

Graz, , Austria

Site Status

Research Site

Innsbruck, , Austria

Site Status

Research Site

Linz, , Austria

Site Status

Research Site

Linz, , Austria

Site Status

Research Site

Salzburg, , Austria

Site Status

Research Site

Vienna, , Austria

Site Status

Research Site

Bonheiden, , Belgium

Site Status

Research Site

Brasschaat, , Belgium

Site Status

Research Site

Brussels, , Belgium

Site Status

Research Site

Charleroi, , Belgium

Site Status

Research Site

Duffel, , Belgium

Site Status

Research Site

Edegem, , Belgium

Site Status

Research Site

Ghent, , Belgium

Site Status

Research Site

Hasselt, , Belgium

Site Status

Research Site

Kortrijk, , Belgium

Site Status

Research Site

Leuven, , Belgium

Site Status

Research Site

Libramont, , Belgium

Site Status

Research Site

Liège, , Belgium

Site Status

Research Site

London, Ontario, Canada

Site Status

Research Site

Sault Ste. Marie, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Montreal, Quebec, Canada

Site Status

Research Site

Québec, Quebec, Canada

Site Status

Research Site

Herlev, , Denmark

Site Status

Research Site

København Ø, , Denmark

Site Status

Research Site

Roskilde, , Denmark

Site Status

Research Site

Berlin, , Germany

Site Status

Research Site

Dresden, , Germany

Site Status

Research Site

Düsseldorf, , Germany

Site Status

Research Site

Düsseldorf, , Germany

Site Status

Research Site

Erlangen, , Germany

Site Status

Research Site

Essen, , Germany

Site Status

Research Site

Essen, , Germany

Site Status

Research Site

Frankfurt am Main, , Germany

Site Status

Research Site

Frankfurt am Main, , Germany

Site Status

Research Site

Freiburg im Breisgau, , Germany

Site Status

Research Site

Hamburg, , Germany

Site Status

Research Site

Hanover, , Germany

Site Status

Research Site

Hanover, , Germany

Site Status

Research Site

Kiel, , Germany

Site Status

Research Site

Konstanz, , Germany

Site Status

Research Site

Leipzig, , Germany

Site Status

Research Site

Ludwigsburg, , Germany

Site Status

Research Site

München, , Germany

Site Status

Research Site

München, , Germany

Site Status

Research Site

München, , Germany

Site Status

Research Site

Oldenburg, , Germany

Site Status

Research Site

Ravensburg, , Germany

Site Status

Research Site

Rostock, , Germany

Site Status

Research Site

Stuttgart, , Germany

Site Status

Research Site

Tübingen, , Germany

Site Status

Research Site

Ulm, , Germany

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Athens, , Greece

Site Status

Research Site

Larissa, , Greece

Site Status

Research Site

Pátrai, , Greece

Site Status

Research Site

Thessaloniki, , Greece

Site Status

Research Site

Hong Kong, , Hong Kong

Site Status

Research Site

Kowloon, , Hong Kong

Site Status

Research Site

New Territories, , Hong Kong

Site Status

Research Site

Avellino, , Italy

Site Status

Research Site

Aviano PN, , Italy

Site Status

Research Site

Bari, , Italy

Site Status

Research Site

Bologna, , Italy

Site Status

Research Site

Brescia, , Italy

Site Status

Research Site

Genova, , Italy

Site Status

Research Site

Milan, , Italy

Site Status

Research Site

Milan, , Italy

Site Status

Research Site

Napoli, , Italy

Site Status

Research Site

Novara, , Italy

Site Status

Research Site

Palermo, , Italy

Site Status

Research Site

Pisa, , Italy

Site Status

Research Site

Roma, , Italy

Site Status

Research Site

Roma, , Italy

Site Status

Research Site

Torino, , Italy

Site Status

Research Site

Nagoya, Aichi-ken, Japan

Site Status

Research Site

Kashiwa, Chiba, Japan

Site Status

Research Site

Fukuoka, Fukuoka, Japan

Site Status

Research Site

Kurume, Fukuoka, Japan

Site Status

Research Site

Kure, Hiroshima, Japan

Site Status

Research Site

Sapporo, Hokkaido, Japan

Site Status

Research Site

Morioka, Iwate, Japan

Site Status

Research Site

Kitaadachi-gun, Saitama, Japan

Site Status

Research Site

Suntou-gun, Shizuoka, Japan

Site Status

Research Site

Yonago, Tottori, Japan

Site Status

Research Site

Tokyo, , Japan

Site Status

Research Site

Tokyo, , Japan

Site Status

Research Site

Deventer, , Netherlands

Site Status

Research Site

Leiden, , Netherlands

Site Status

Research Site

Nijmegen, , Netherlands

Site Status

Research Site

Rotterdam, , Netherlands

Site Status

Research Site

Chelyabinsk, , Russia

Site Status

Research Site

Ivanovo, , Russia

Site Status

Research Site

Krasnodar, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Obninsk, , Russia

Site Status

Research Site

Pyatigorsk, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Ufa, , Russia

Site Status

Research Site

Voronezh, , Russia

Site Status

Research Site

Goyang-si, Gyeonggi-do, , South Korea

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Seoul, , South Korea

Site Status

Research Site

Zaragoza, Aragon, Spain

Site Status

Research Site

Palma de Mallorca, Balearic Islands, Spain

Site Status

Research Site

Badalona, Catalonia, Spain

Site Status

Research Site

Barcelona, Catalonia, Spain

Site Status

Research Site

Girona, Catalonia, Spain

Site Status

Research Site

Lleida, Catalonia, Spain

Site Status

Research Site

Madrid, Madrid, Spain

Site Status

Research Site

Madrid, Madrid, Spain

Site Status

Research Site

Madrid, Madrid, Spain

Site Status

Research Site

Madrid, Madrid, Spain

Site Status

Research Site

Madrid, Madrid, Spain

Site Status

Research Site

Madrid, Madrid, Spain

Site Status

Research Site

Madrid, Madrid, Spain

Site Status

Research Site

Madrid, Madrid, Spain

Site Status

Research Site

El Palmar, Murcia, Spain

Site Status

Research Site

Oviedo, Principality of Asturias, Spain

Site Status

Research Site

Valencia, Valencia, Spain

Site Status

Research Site

Valencia, Valencia, Spain

Site Status

Research Site

Valencia, Valencia, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Belgium Canada Denmark Germany Greece Hong Kong Italy Japan Netherlands Russia South Korea Spain

References

Explore related publications, articles, or registry entries linked to this study.

Fujiwara K, Monk BJ, Lhomme C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F. Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1). Ann Oncol. 2016 Jun;27(6):1006-1013. doi: 10.1093/annonc/mdw147. Epub 2016 Mar 30.

Reference Type BACKGROUND
PMID: 27029706 (View on PubMed)

Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.

Reference Type DERIVED
PMID: 37185961 (View on PubMed)

Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.

Reference Type DERIVED
PMID: 31076365 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TRINOVA-3 20101129/ENGOT-ov2

Identifier Type: -

Identifier Source: secondary_id

20101129

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PTX-200 and Carboplatin in Ovarian Cancer
NCT01690468 TERMINATED PHASE1/PHASE2